Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma.

Glioblastoma (GBM) is an aggressive and devastating primary brain cancer which responds very poorly to treatment. The average survival time of patients is only 14–15 months from diagnosis so there is a clear and unmet need for the development of novel targeted therapies to improve patient outcomes. The multifunctional cytokine TGFβ plays fundamental roles in development, adult tissue homeostasis, tissue wound repair and immune responses. Dysfunction of TGFβ signalling has been implicated in both the development and progression of many tumour types including GBM, thereby potentially providing an actionable target for its treatment. This review will examine TGFβ signalling mechanisms and their role in the development and progression of GBM. The targeting of TGFβ signalling using a variety of approaches including the TGFβ binding protein Decorin will be highlighted as attractive therapeutic strategies. • TGFβ can act as a context dependent tumour suppressor and tumour promoter in GBM. • TGFβ can modulate GBM tumour cell proliferation, migration, invasion and stemness. • TGFβ can modulate the tumour microenvironment in GBM. • TGFβ signalling is a promising target for therapeutic intervention for some GBM. • DCN may have therapeutic potential in GBM. [ABSTRACT FROM AUTHOR]